GNI Group Ltd.
Stock Price Chart
2026/11/17 14:34 UpdatedPrice Trend
2026/11/17 14:34 UpdatedPrice & Trading Details
2026/11/17 14:34 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/02/12 | ¥224.64 | ¥-74.44 | -133.1% |
| 2025/11/13 | ¥10.82 | ¥8.54 | -21.1% |
| 2025/08/14 | ¥-109.70 | ¥-7.62 | +93.1% |
| 2025/05/15 | ¥27.86 | ¥-10.57 | -137.9% |
Shareholder Composition
Updated 2026/11/01Financial Performance
2026/11/15 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥12,690M | ¥17,419M | ¥26,011M | ¥23,612M |
| Gross Profit | ¥11,090M | ¥14,745M | ¥22,431M | ¥18,037M |
| Operating Income | ¥1,625M | ¥1,378M | ¥13,109M | ¥1,402M |
| Pretax Income | ¥1,755M | ¥1,638M | ¥13,863M | ¥2,119M |
| Net Income | ¥1,066M | ¥389M | ¥8,094M | ¥1,098M |
| EPS | ¥22.08 | ¥8.11 | ¥165.56 | ¥21.15 |
| Operating Margin | 12.80% | 7.91% | 50.40% | 5.94% |
| Balance Sheet | ||||
| Total Assets | ¥30,296M | ¥33,907M | ¥64,269M | ¥71,943M |
| Total Equity | ¥18,860M | ¥20,970M | ¥33,794M | ¥36,446M |
| Total Liabilities | ¥11,436M | ¥12,937M | ¥30,475M | ¥35,497M |
| Cash | ¥14,352M | ¥11,049M | ¥21,633M | ¥10,115M |
| Interest-bearing Debt | ¥1,126M | ¥537M | ¥3,699M | ¥7,206M |
| Equity Ratio | 62.25% | 61.84% | 52.58% | 50.66% |
| D/E Ratio | 0.06 | 0.03 | 0.11 | 0.20 |
| Cash Flow | ||||
| Operating CF | ¥552M | ¥393M | ¥6,549M | -¥3,164M |
| Investing CF | -¥261M | -¥4,116M | -¥6,843M | -¥10,361M |
| Financing CF | ¥2,853M | -¥646M | ¥10,687M | ¥694M |
| Free CF | -¥142M | -¥1,547M | ¥4,473M | -¥4,701M |
| Efficiency | ||||
| ROE | 5.65% | 1.85% | 23.95% | 3.01% |
| ROA | 3.52% | 1.15% | 12.59% | 1.53% |
Latest IR Information
-
We Bring New Hope to Life 2026 Fiscal Year Q3 Earnings Presentation
With the consolidation of Ayumi Pharmaceutical and progress in the F351 NDA application, the company is entering a growth phase toward becoming a global biopharma. Revenue for July–September increased 53.6% year-over-year; acquisition-related expenses for Ayumi Pharmaceutical temporarily raised costs. Full-year...
Read more -
Fiscal Year Ending December 2026 Third Quarter Financial Summary〔IFRS〕(Consolidated)
For the third quarter of the fiscal year ending December 2026, consolidated revenue was 29,731 million yen, a significant year-over-year increase. Operating income turned positive to 73 million yen. With the acquisition of Ayumi Pharmaceutical Holdings as a wholly owned...
Read more -
Gyre Therapeutics Q3 FY2026 Financial Results and Progress of Regulatory Review for F351
Announcement of Gyre Therapeutics' Q3 FY2026 results and progress of NMPA review for F351 (therapy for liver fibrosis). NMPA on-site inspection completed; approval decision expected late 2026 or Q1 2027.
Read more -
From Growth Market to TOPIX — GNI Group Newly Included in TOPIX in First Post-Reform Regular Rebalancing
Inclusion in TOPIX was decided, with incorporation starting on 2026-10-30. With a view to expanding exposure to institutional investors and stabilizing the shareholder base, the company aims to enhance long-term value based on its global expansion and growth strategy in...
Read more -
Notice Regarding FDA Approval of Accelagen™ Plus Surgical Matrix
BAB, a consolidated subsidiary, obtained FDA 510(k) clearance for Accelagen™ Plus Surgical Matrix, a private-brand product. Aiming to commence sales in the United States in Q1 2027, we are pursuing private-branding of the MedTech business. Minor impact on the consolidated...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,400
Rating Score: 1.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.